<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077437</url>
  </required_header>
  <id_info>
    <org_study_id>MAPP2</org_study_id>
    <nct_id>NCT04077437</nct_id>
  </id_info>
  <brief_title>A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multi-Site Phase 3 Study of the Efficacy and Safety of Manualized MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder of Moderate or Greater Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multidisciplinary Association for Psychedelic Studies</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Multidisciplinary Association for Psychedelic Studies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder that can develop&#xD;
      after a traumatic life experience that severely reduces quality of life. This multi-site,&#xD;
      double-blind, placebo-controlled, randomized Phase 3 study will assess the efficacy and&#xD;
      safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy compared to&#xD;
      psychotherapy with placebo in participants diagnosed with at least moderate PTSD. The study&#xD;
      will be conducted in up to N ≈ 100 participants. Participants will be randomized to receive a&#xD;
      flexible dose of 80 or 120 mg MDMA or placebo, followed by a supplemental half-dose of 40 or&#xD;
      60 mg MDMA or placebo, unless contraindicated, with manualized psychotherapy in three monthly&#xD;
      Experimental Sessions. This ~12-week Treatment Period will be preceded by three Preparatory&#xD;
      Sessions with the participant and therapists. During the Treatment Period, each Experimental&#xD;
      Session will be followed by three Integrative Sessions of non-drug psychotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Posttraumatic stress disorder (PTSD) is a debilitating psychiatric disorder that can develop&#xD;
      after a person experiences a traumatic event, such as sexual assault, war, or any other&#xD;
      life-threatening event. PTSD is a worldwide health problem that severely reduces a person's&#xD;
      quality of life and is associated with high rates of psychiatric and medical comorbidity,&#xD;
      disability, suffering, and suicide. At least a third of PTSD patients fail to respond to&#xD;
      established PTSD psychotherapies. A wider array of effective treatments for PTSD are needed.&#xD;
&#xD;
      3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy may be a potential treatment&#xD;
      option for PTSD. MDMA is a monoamine releaser that affects serotonin, norepinephrine, and&#xD;
      dopamine. MDMA is capable of inducing unique psychopharmacological effects such as decreased&#xD;
      feelings of fear, increased feelings of wellbeing, increased sociability and extroversion,&#xD;
      increased interpersonal trust, and an alert state of consciousness. In the U.S., MDMA was&#xD;
      used as an adjunct to psychotherapy by a considerable number of psychiatrists and therapists&#xD;
      before it was placed in Schedule I in 1985 as a result of non-medical use.&#xD;
&#xD;
      This multi-site, double-blind, placebo-controlled, randomized Phase 3 study will assess the&#xD;
      efficacy and safety of MDMA-assisted psychotherapy versus psychotherapy with placebo control&#xD;
      in participants diagnosed with at least moderate PTSD. The study will be conducted in N ≈ 100&#xD;
      participants. Participants will be randomized into one of two groups (MDMA or placebo) in a&#xD;
      1:1 ratio. A flexible dose of MDMA or placebo, followed by a supplemental half-dose unless&#xD;
      contraindicated, will be administered during the Treatment Period with manualized&#xD;
      psychotherapy in three monthly Experimental Sessions. This ~12-week Treatment Period will be&#xD;
      preceded by three Preparatory Sessions with the participant and therapists. Initial doses in&#xD;
      each Experimental Session will be 80 mg or 120 mg of MDMA compounded with mannitol and&#xD;
      magnesium stearate or placebo alone (mannitol and magnesium stearate), followed 1.5 to 2&#xD;
      hours later by a supplemental half-dose (40 or 60 mg, respectively). Total amounts of MDMA to&#xD;
      be administered per Experimental Session range from 80 mg to 180 mg. Each Experimental&#xD;
      Session will be followed by three Integrative Sessions of non-drug psychotherapy to help the&#xD;
      participants process and understand their experiences during the Experimental Sessions.&#xD;
&#xD;
      The primary objective of this study is to evaluate the efficacy of MDMA-assisted&#xD;
      psychotherapy for PTSD compared to identical psychotherapy with inactive placebo, as measured&#xD;
      by change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score from&#xD;
      Visit 3 (Baseline) to Visit 19 (18 weeks post Baseline) (Blake et al., 1995). The key&#xD;
      secondary objective of this study is to evaluate the efficacy of MDMA-assisted psychotherapy&#xD;
      for PTSD compared to identical psychotherapy with inactive placebo in clinician-rated&#xD;
      functional impairment, as measured by the change in Sheehan Disability Scale (adapted SDS)&#xD;
      item scores from Visit 3 (Baseline) to Visit 19 (18 weeks post Baseline) (Leon et al., 1997).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">March 5, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind between group comparison of change in PTSD symptoms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Use of separate databases for outcome measures and safety data. Assessment made by pool of independent raters. Randomization will be managed via an Interactive Web Randomization System (IWRS) based on a centralized randomization schedule developed by an independent thirdparty vendor to maintain blinding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Clinician-Administered PTSD for DSM 5</measure>
    <time_frame>18 weeks post baseline post enrollment confirmation</time_frame>
    <description>Global severity Scores on the CAPS-5, a measure of PTSD symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Sheehan Disability Scale (adapted SDS) total score</measure>
    <time_frame>18 weeks post enrollment confirmation</time_frame>
    <description>Sheehan Disability Scale (adapted SDS) total score, a measure of clinician-rated functional impairment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Posttraumatic Stress Disorder</condition>
  <arm_group>
    <arm_group_label>Experimental: MDMA-assisted psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of 80 to 120 mg MDMA in combination with psychotherapy, followed by a supplemental half-dose of 40 or 60 mg MDMA offered 1.5 to 2 hrs after the initial dose, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of inactive placebo in combination with psychotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral: Psychotherapy</intervention_name>
    <description>Standardized non-directive psychotherapy performed by therapist team.</description>
    <arm_group_label>Experimental: MDMA-assisted psychotherapy</arm_group_label>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <other_name>Manualized MDMA-assisted psychotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MDMA</intervention_name>
    <description>Administration of 80 to 120 mg MDMA during three sessions of MDMA-assisted psychotherapy, followed by a supplemental half-dose of 40 or 60 mg MDMA offered 1.5 to 2 hrs after the initial dose, respectively.</description>
    <arm_group_label>Experimental: MDMA-assisted psychotherapy</arm_group_label>
    <other_name>3,4-methylenedioxymethamphetamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo during three sessions of MDMA-assisted psychotherapy.</description>
    <arm_group_label>Placebo Comparator: Placebo</arm_group_label>
    <other_name>Inactive placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are at least 18 years old.&#xD;
&#xD;
          -  Are fluent in speaking and reading the predominantly used or recognized language of&#xD;
             the study site.&#xD;
&#xD;
          -  Are able to swallow pills.&#xD;
&#xD;
          -  Agree to have study visits recorded, including Experimental Sessions, Independent&#xD;
             Rater assessments, and non-drug psychotherapy sessions.&#xD;
&#xD;
          -  Must provide a contact (relative, spouse, close friend or other caregiver) who is&#xD;
             willing and able to be reached by the investigators in the event of a participant&#xD;
             becoming suicidal or unreachable.&#xD;
&#xD;
          -  Must agree to inform the investigators within 48 hours of any medical conditions and&#xD;
             procedures.&#xD;
&#xD;
          -  If of childbearing potential, must have a negative pregnancy test at study entry and&#xD;
             prior to each Experimental Session, and must agree to use adequate birth control&#xD;
             through 10 days after the last Experimental Session.&#xD;
&#xD;
          -  Must not participate in any other interventional clinical trials during the duration&#xD;
             of the study.&#xD;
&#xD;
          -  Must be willing to remain overnight at the study site after each Experimental Session&#xD;
             and be driven home after, and commit to medication dosing, therapy, and study&#xD;
             procedures.&#xD;
&#xD;
          -  At baseline, have moderate PTSD diagnosis.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are not able to give adequate informed consent.&#xD;
&#xD;
          -  Have uncontrolled hypertension.&#xD;
&#xD;
          -  Have a marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration&#xD;
             of a QTc interval &gt;450 milliseconds [ms] corrected by Bazett's formula).&#xD;
&#xD;
          -  Have a history of additional risk factors for Torsade de pointes (e.g., heart failure,&#xD;
             hypokalemia, family history of Long QT Syndrome).&#xD;
&#xD;
          -  Have evidence or history of significant medical disorders.&#xD;
&#xD;
          -  Have symptomatic liver disease.&#xD;
&#xD;
          -  Have history of hyponatremia or hyperthermia.&#xD;
&#xD;
          -  Weigh less than 48 kilograms (kg).&#xD;
&#xD;
          -  Are pregnant or nursing, or are of childbearing potential and are not practicing an&#xD;
             effective means of birth control.&#xD;
&#xD;
          -  Are abusing illegal drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Mithoefer, MD</last_name>
    <role>Study Director</role>
    <affiliation>MAPS Public Benefit Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Officer</last_name>
    <phone>(215) 645-2466</phone>
    <email>recruitment@mapsbcorp.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New School Research LLC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>818-643-5234</phone>
      <email>info@newschoolresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Francisco Insight and Integration Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>415-400-5722</phone>
      <email>info@sfinsightcenter.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>510-985-3522</phone>
      <email>mdma.research@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aguazul-Blue Water Inc.</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>720-892-8395</phone>
      <email>info.boulderstudy@comcast.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wholeness Center</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <zip>80525</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>970-825-6610</phone>
      <email>wcresearch@wholeness.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ray Worthy Psychiatry LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Trauma Research Foundation</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>617-906-6690</phone>
      <email>mdma.study.boston@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>646-501-4206</phone>
      <email>MDMA.Research@nyumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Private Practice</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>917-830-4948</phone>
      <email>info@mdma.nyc</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zen Therapeutic Solutions, LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>843-882-5203</phone>
      <email>information.zts@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin at Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>608-225-0718</phone>
      <email>Maps.madison@mailplus.wisc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Health Center</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5R 5H3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>604-360-1850</phone>
      <email>maps.trial.bc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Research Fund</name>
      <address>
        <city>Be'er Ya'aqov</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972-8-9258396</phone>
      <email>bymehkar@moh.gov.il</email>
    </contact>
    <contact_backup>
      <phone>+972-8-9258474</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sheba Fund for Health Services and Research</name>
      <address>
        <city>Tel HaShomer</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+972-3-5303773</phone>
      <email>mdmastudysheba@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mdmaptsd.org/</url>
    <description>Recruitment Website: Please click on link to apply.</description>
  </link>
  <reference>
    <citation>Leon AC, Olfson M, Portera L, Farber L, Sheehan DV. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. Int J Psychiatry Med. 1997;27(2):93-105.</citation>
    <PMID>9565717</PMID>
  </reference>
  <reference>
    <citation>Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Gusman FD, Charney DS, Keane TM. The development of a Clinician-Administered PTSD Scale. J Trauma Stress. 1995 Jan;8(1):75-90. Review.</citation>
    <PMID>7712061</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 30, 2019</study_first_submitted>
  <study_first_submitted_qc>August 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-Methyl-3,4-methylenedioxyamphetamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will share outcome data appearing in any published reports upon request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data and study-related documents will be available when the database has been locked and data has been unblinded.</ipd_time_frame>
    <ipd_access_criteria>Interested persons should correspond with the central contact for the multisite study.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

